levodopa has been researched along with rotenone in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 5 (22.73) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Itakura, T; Nakai, K; Nakao, N | 1 |
| Alam, M; Mayerhofer, A; Schmidt, WJ | 1 |
| Alam, M; Schmidt, WJ | 1 |
| Birman, S; Coulom, H | 1 |
| Ding, JH; Hu, G; Liu, SY; Liu, X; Long, Y; Sun, YH; Wang, F; Wang, H; Wu, J; Yang, Y; Yao, HH | 1 |
| Abdin, AA; Hamouda, HE | 1 |
| Acs, A; Farkas, A; Gyori, J; Szabó, H; Vehovszky, A | 1 |
| Abdin, AA; Sarhan, NI | 1 |
| Aglan, H; Ahmed, H; Atta, H; Ghazy, M; Salem, A | 1 |
| de Groot, MWGDM; Westerink, RHS | 1 |
| Ivanova, EA; Kapitsa, IG; Pozdnev, VF; Valdman, EA; Voronina, TA; Zolotov, NN | 1 |
| Mbiydzenyuy, NE; Ninsiima, HI; Pieme, CA; Valladares, MB | 1 |
| Abd El Fattah, MA; Badawi, GA; El Sayed, MI; Zaki, HF | 1 |
| Margabandhu, G; Vanisree, AJ | 1 |
| Abdelrahman, A; Ahmed, OG; Mahmoud, ME; Monir, DM; Rehan, IF | 1 |
| Khurana, N; Muthuraman, A; Sharma, N; Utreja, P | 1 |
| Atlas, D; Wiesen, T | 1 |
| Azar, YO; Badawi, GA; Ibrahim, SM; Zaki, HF | 1 |
22 other study(ies) available for levodopa and rotenone
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Metabolic inhibition enhances selective toxicity of L-DOPA toward mesencephalic dopamine neurons in vitro.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Antioxidants; Cells, Cultured; Dizocilpine Maleate; Dopamine; Dopamine Agents; Drug Synergism; Excitatory Amino Acid Antagonists; Levodopa; Mesencephalon; NAD(P)H Dehydrogenase (Quinone); Neurons; Oxidative Stress; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rotenone; Uncoupling Agents | 1997 |
The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Catalepsy; Chromatography, High Pressure Liquid; Dopamine; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Reaction Time; Rotenone; Statistics, Nonparametric; Time Factors | 2004 |
L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Corpus Striatum; Dopamine; Drug Synergism; Electron Transport Complex I; Levodopa; Male; Motor Activity; Motor Skills; Muscle Rigidity; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Uncoupling Agents | 2004 |
Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster.
Topics: Animals; Antioxidants; Apoptosis; Brain; Cell Count; Dopamine; Dopamine Agonists; Drosophila melanogaster; Electron Transport Complex I; Insecticides; Levodopa; Locomotion; Melatonin; Nerve Degeneration; Neurons; Oxidative Stress; Parkinsonian Disorders; Phenotype; Rotenone | 2004 |
Activation of mitochondrial ATP-sensitive potassium channels improves rotenone-related motor and neurochemical alterations in rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Catalepsy; Decanoic Acids; Diazoxide; Disease Models, Animal; Dopamine; Hydroxy Acids; Levodopa; Male; Motor Activity; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Parkinsonian Disorders; Potassium Channel Blockers; Potassium Channels; Propylamines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotenone; Substantia Nigra | 2006 |
Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism.
Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Levodopa; Mitochondria; NAD; Neurons; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2; Psychomotor Performance; Rats; Rotenone; Spectrophotometry; Ubiquinone; Ultrasonography; Vitamins | 2008 |
Effects of rotenone and other mitochondrial complex I inhibitors on the brine shrimp Artemia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Artemia; Biological Assay; Biotransformation; Electron Transport Complex I; Glutathione Transferase; Herbicides; Inactivation, Metabolic; Levodopa; Rotenone | 2010 |
Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity.
Topics: Animals; Antiparkinson Agents; Apoptosis; Disease Models, Animal; Levodopa; Mitochondria; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Rats; Rotenone; Thioctic Acid; Uncoupling Agents | 2011 |
Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson's disease in rat model?
Topics: Adipose Tissue; Amino Acids; Animals; Antigens, CD; Brain; Brain-Derived Neurotrophic Factor; Carbidopa; Cell Differentiation; Cells, Cultured; Chemokine CCL2; Disease Models, Animal; Drug Combinations; Female; Gene Expression; Genes, sry; Levodopa; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Ovariectomy; Parkinson Disease; Rats, Sprague-Dawley; Rotenone; Transforming Growth Factor beta; Tyrosine 3-Monooxygenase | 2014 |
Chemically-induced oxidative stress increases the vulnerability of PC12 cells to rotenone-induced toxicity.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Antiparkinson Agents; Calcium; Cell Survival; Dose-Response Relationship, Drug; Ferrous Compounds; Insecticides; Levodopa; Oxidative Stress; PC12 Cells; Rats; Rotenone; Time Factors | 2014 |
[Effect of afobazole and levodopa on the activity of proline-specific proteinases and adenosine deaminase in blood serum and brain structures of rats with experimental Parkinson's syndrome induced by systemic administration of rotenone].
Topics: Adenosine Deaminase; Animals; Benzimidazoles; Brain; Dipeptidyl Peptidase 4; Levodopa; Morpholines; Parkinson Disease, Secondary; Proline; Prolyl Oligopeptidases; Rats; Rotenone; Serine Endopeptidases; Serum | 2017 |
Zinc and linoleic acid pre-treatment attenuates biochemical and histological changes in the midbrain of rats with rotenone-induced Parkinsonism.
Topics: Animals; Antioxidants; Disease Models, Animal; Female; Glutathione; Levodopa; Linoleic Acid; Lipid Peroxidation; Parkinsonian Disorders; Rats, Wistar; Rotenone; Zinc | 2018 |
Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Levodopa; Liraglutide; Male; Motor Activity; Parkinsonian Disorders; Pars Compacta; Random Allocation; Rats, Wistar; Rotenone; Sitagliptin Phosphate | 2019 |
Dopamine, a key factor of mitochondrial damage and neuronal toxicity on rotenone exposure and also parkinsonic motor dysfunction-Impact of asiaticoside with a probable vesicular involvement.
Topics: Animals; Antiparkinson Agents; bcl-2-Associated X Protein; Cell Death; Corpus Striatum; Dopamine; Dopaminergic Neurons; Levodopa; Neuronal Outgrowth; Neuroprotective Agents; Parkinsonian Disorders; PC12 Cells; Proto-Oncogene Proteins c-bcl-2; Rats; Rotenone; Triterpenes | 2020 |
Forced exercise activates the NrF2 pathway in the striatum and ameliorates motor and behavioral manifestations of Parkinson's disease in rotenone-treated rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Gait Disorders, Neurologic; Levodopa; Male; Memory, Short-Term; Movement Disorders; Neostriatum; NF-E2-Related Factor 2; Parkinson Disease, Secondary; Physical Conditioning, Animal; Psychomotor Performance; Rats; Rats, Wistar; Rotenone; Signal Transduction; Tyrosine 3-Monooxygenase; Uncoupling Agents; Up-Regulation | 2020 |
Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson's disease rat model.
Topics: Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Body Weight; Carbidopa; Catalase; Catalepsy; Disease Models, Animal; Dopamine; Drug Combinations; Female; Glutathione; Levodopa; Locomotion; Male; Mesencephalon; Muscular Diseases; Oxidative Stress; Parkinson Disease; Postural Balance; Rats, Sprague-Dawley; Rotenone; Superoxides; Thiobarbituric Acid Reactive Substances; Vanillic Acid | 2021 |
Novel anti-apoptotic L-DOPA precursors SuperDopa and SuperDopamide as potential neuroprotective agents for halting/delaying progression of Parkinson's disease.
Topics: Animals; Antioxidants; Dopaminergic Neurons; HEK293 Cells; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Rats; Rotenone | 2022 |
Agmatine-mediated inhibition of NMDA receptor expression and amelioration of dyskinesia via activation of Nrf2 and suppression of HMGB1/RAGE/TLR4/MYD88/NF-κB signaling cascade in rotenone lesioned rats.
Topics: Agmatine; Animals; Antioxidants; Dyskinesias; HMGB1 Protein; Levodopa; Myeloid Differentiation Factor 88; NF-E2-Related Factor 2; NF-kappa B; Oxidopamine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate; Rotenone; Signal Transduction; Toll-Like Receptor 4 | 2022 |